Kiniksa Pharmaceuticals (NASDAQ:KNSA) Target Raised by BofA Securities to $40.00

0
28
Close up and focused stock market business investment candlestick chart - Economy and trading concept. 3D illustration.

Kiniksa Pharmaceuticals stock has undergone multiple analysts rating changes in the recent past.  Kiniksa Pharmaceuticals stock Target Raised by   BofA Securities on 6/29/2020. In a note to investors, the firm issued a new target price of $40.00. The analysts previously had $25.00 target price. BofA Securities’s price target would indicate a potential upside of 46.20% from the stock’s previous close.

Shares of Kiniksa Pharmaceuticals traded up $2.97 on Monday, reaching $26.00. 0 shares of the stock traded hands, compared to its average volume of 258557. Shares of were trading at $26.00 on Monday. The firm’s 50 day moving average is $$21.68 and its 200 day moving average is $14.61.Kiniksa Pharmaceuticals  has a 12 month low of $25.44 and a 12 month high of $28.67. While on yearly highs and lows, Kiniksa Pharmaceuticals today has traded high as $28.67 and has touched $25.44 on the downward trend.

Kiniksa Pharmaceuticals Earnings and What to expect: 

Kiniksa Pharmaceuticals last issued its earnings data on April 28th, 2020. The reported ($0.48) EPS for the quarter, beating the consensus estimate of ($0.63) by $0.15. Kiniksa Pharmaceuticals has generated ($2.99) earnings per share over the last year. Kiniksa Pharmaceuticals has not formally confirmed its next earnings publication date, but the company’s estimated earnings date is Monday, August 10th, 2020 based off prior year’s report dates.

Earnings for Kiniksa Pharmaceuticals are expected to decrease in the coming year, from ($2.31) to ($2.42) per share. The P/E ratio of Kiniksa Pharmaceuticals is -11.66, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. The P/E ratio of Kiniksa Pharmaceuticals is -11.66, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. Kiniksa Pharmaceuticals has a P/B Ratio of 6.34. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Latest Insiders Trading and Volume : 

  • Insider Ownership Percentage: 59.92%
  • On 6/10/2020 EVP Thomas W Beetham Sell 13,752 at average share price of $25.07 which equates to $344,762.64 in money value.
  • On 4/20/2020 EVP Thomas W Beetham Sell 47,423 at average price of  $19.06 with total value of : Not Data Available
  • On 3/6/2020 CEO Sanj K Patel Sell 33,115 at average price of  $20.00 with total value of : $662,300.00
  • See More Analyst Rating at: RATING

Other Analyst’s rating for Kiniksa Pharmaceuticals

  • 6/29/2020 – Kiniksa Pharmaceuticals had its price target raised by analysts at BofA Securities from $25.00 to $40.00. They now have a “buy” rating on the stock.
  • 6/29/2020 – Kiniksa Pharmaceuticals had its price target raised by analysts at Wedbush from $30.00 to $38.00.
  • 4/29/2020 – Kiniksa Pharmaceuticals was upgraded by analysts at BidaskClub from a “hold” rating to a “buy” rating.
  • 4/23/2020 – Kiniksa Pharmaceuticals was upgraded by analysts at Zacks Investment Research from a “hold” rating to a “buy” rating. They now have a $23.00 price target on the stock.
  • See More Analyst Rating at: RATING

Other rating updates by BofA Securities: 

  • 6/29/2020 – Kiniksa Pharmaceuticals had its price target raised by analysts at BofA Securities from $25.00 to $40.00. They now have a “buy” rating on the stock.
  • 6/29/2020 – ZoomInfo Technologies is now covered by analysts at BofA Securities. They set a “buy” rating and a $60.00 price target on the stock.
  • 6/29/2020 – Bain Capital Specialty Finance was downgraded by analysts at BofA Securities from a “buy” rating to a “neutral” rating.
  • 6/29/2020 – Mosaic was upgraded by analysts at BofA Securities from an “underperform” rating to a “buy” rating. They now have a $15.00 price target on the stock, up previously from $12.00.
  • See More Analyst Rating at: RATING

Kiniksa Pharmaceuticals (NASDAQ:KNSA) Moving Average Technical Analysis

5 day Moving Average is $$24.66 And 5 day price change is $0.99 (3.96%)  with average volume for 5 day average is 487,560. While technical analysis for average 20 days shows significant difference, 20 day moving average is  $23.34 and 20 day price change is $4.43 (20.54%) and average 20 day moving volume is 307,370. 50 day moving average is $21.68  and 50 day price change is $7.62 ( 41.46%)  and with average volume for 50 days is : 294,464. 200 day moving average is $14.61  and 200 day price change is $16.50 (173.68%)  and with average volume for 200 days is : 259,831.

See More Analyst Rating at: RATING